Alizyme acquires SmithKline's renzapride rights

Alizyme (LSE:AZM) acquired partner SmithKline's rights to renzapride (ATL-1251) to treat irritable bowel syndrome. This follows discussions between SmithKline (LSE:SB; SBH) and the U.S. Federal Trade ...